Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Product, By Region and Competition, 2020-2030F

Description

The Global Biosimilars Market will grow from USD 31.07 Billion in 2024 to USD 42.36 Billion by 2030 at a 5.30% CAGR. Biosimilars are biological medical products highly similar to an already approved original biologic, known as the reference product, demonstrating no clinically meaningful differences in safety, purity, and effectiveness. The global biosimilars market's growth is primarily driven by the imminent patent expiry of numerous blockbuster biologics, compelling the demand for more affordable therapeutic alternatives, alongside the increasing prevalence of chronic diseases globally.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 31.07 Billion
Market Size 2030	USD 42.36 Billion
CAGR 2025-2030	5.30%
Fastest Growing Segment	Oncology
Largest Market	North America

Key Market Drivers

The global biosimilars market expansion is fundamentally propelled by the imminent patent expiration of numerous high-value biologic drugs, creating substantial opportunities for more affordable alternatives. The pharmaceutical industry is currently navigating a significant $236 billion patent cliff projected between 2025 and 2030, with nearly 70 blockbuster products set to lose exclusivity and open their therapeutic areas to biosimilar competition. This widespread loss of exclusivity acts as a primary catalyst, enabling biosimilar manufacturers to develop and launch products that directly compete with established biologics.

Key Market Challenges

The inherent manufacturing complexities and high associated costs represent a significant impediment to the global biosimilars market's expansion. Developing and producing biosimilar products requires extensive investment in research, highly specialized manufacturing facilities, and stringent purification processes due to their intricate biological nature. These factors directly contribute to extended development timelines and elevated capital expenditure for biosimilar manufacturers, creating substantial financial outlay and technical hurdles.

Key Market Trends

The global biosimilars market is significantly influenced by the expansion into GLP-1 agonist biosimilars, marking a strategic pivot towards high-demand therapeutic areas. This trend addresses the substantial patient populations grappling with chronic conditions such as type 2 diabetes and obesity, promising to broaden access and alleviate healthcare costs. The entry of biosimilar versions of these highly effective drugs is poised to intensify competition and foster innovation within this lucrative segment.

Key Market Players

Dr. Reddy's Laboratories Ltd.
Sandoz Group AG
Coherus Biosciences
Viatris Inc.
Bio-Thera Solutions
Pfizer Inc.
Apobiologix
Teva Pharmaceuticals
Biocon Ltd
Reliance Life Sciences

Report Scope:

In this report, the Global Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilars Market, By Indication:

Oncology
Inflammatory and autoimmune diseases
Chronic diseases
Blood disorders
Growth hormone deficiency
Infectious diseases
Others

Biosimilars Market, By Product:

Monoclonal antibodies
Insulin
Granulocyte colony-stimulating factor
Erythropoietin
Recombinant human growth hormone
Etanercept
follitropin
Teriparatide
Interferons
Anticoagulants
Others

Biosimilars Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biosimilars Market.

Available Customizations:

Global Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilars Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Indication (Oncology, Inflammatory and autoimmune diseases, Chronic diseases, Blood disorders, Growth hormone deficiency, Infectious diseases, Others)
- 5.2.2. By Product (Monoclonal antibodies, Insulin, Granulocyte colony-stimulating factor, Erythropoietin, Recombinant human growth hormone, Etanercept, follitropin, Teriparatide, Interferons, Anticoagulants, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Biosimilars Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Indication
- 6.2.2. By Product
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Biosimilars Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Indication
    - 6.3.1.2.2. By Product
- 6.3.2. Canada Biosimilars Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Indication
    - 6.3.2.2.2. By Product
- 6.3.3. Mexico Biosimilars Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Indication
    - 6.3.3.2.2. By Product

7. Europe Biosimilars Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Product
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Biosimilars Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Indication
    - 7.3.1.2.2. By Product
- 7.3.2. France Biosimilars Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Indication
    - 7.3.2.2.2. By Product
- 7.3.3. United Kingdom Biosimilars Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Indication
    - 7.3.3.2.2. By Product
- 7.3.4. Italy Biosimilars Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Indication
    - 7.3.4.2.2. By Product
- 7.3.5. Spain Biosimilars Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Indication
    - 7.3.5.2.2. By Product

8. Asia Pacific Biosimilars Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Product
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Biosimilars Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Indication
    - 8.3.1.2.2. By Product
- 8.3.2. India Biosimilars Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Indication
    - 8.3.2.2.2. By Product
- 8.3.3. Japan Biosimilars Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Indication
    - 8.3.3.2.2. By Product
- 8.3.4. South Korea Biosimilars Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Indication
    - 8.3.4.2.2. By Product
- 8.3.5. Australia Biosimilars Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Indication
    - 8.3.5.2.2. By Product

9. Middle East & Africa Biosimilars Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Product
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Biosimilars Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Indication
    - 9.3.1.2.2. By Product
- 9.3.2. UAE Biosimilars Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Indication
    - 9.3.2.2.2. By Product
- 9.3.3. South Africa Biosimilars Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Indication
    - 9.3.3.2.2. By Product

10. South America Biosimilars Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Product
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Biosimilars Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Indication
    - 10.3.1.2.2. By Product
- 10.3.2. Colombia Biosimilars Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Indication
    - 10.3.2.2.2. By Product
- 10.3.3. Argentina Biosimilars Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Indication
    - 10.3.3.2.2. By Product

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Biosimilars Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Dr. Reddy's Laboratories Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Sandoz Group AG
15.3. Coherus Biosciences
15.4. Viatris Inc.
15.5. Bio-Thera Solutions
15.6. Pfizer Inc.
15.7. Apobiologix
15.8. Teva Pharmaceuticals
15.9. Biocon Ltd
15.10. Reliance Life Sciences